Article Versions Notes

Vermij L, Horeweg N, Leon-Castillo A, Rutten TA, Mileshkin LR, Mackay HJ, Leary A, Powell ME, Singh N, Crosbie EJ, et al. HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. Cancers. 2021; 13(1):44. https://doi.org/10.3390/cancers13010044

Vermij, Lisa, Nanda Horeweg, Alicia Leon-Castillo, Tessa A. Rutten, Linda R. Mileshkin, Helen J. Mackay, Alexandra Leary, Melanie E. Powell, Naveena Singh, Emma J. Crosbie, and et al. 2021. "HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes" Cancers 13, no. 1: 44. https://doi.org/10.3390/cancers13010044

Vermij, L., Horeweg, N., Leon-Castillo, A., Rutten, T. A., Mileshkin, L. R., Mackay, H. J., Leary, A., Powell, M. E., Singh, N., Crosbie, E. J., Smit, V. T. H. B. M., Creutzberg, C. L., & Bosse, T. (2021). HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. Cancers, 13(1), 44. https://doi.org/10.3390/cancers13010044